China Regional Advisory Council

Chair

Jingsong Wang

Chief Executive Officer, Harbour Biomed

  
Jingsong Wang, MD, PhD, is CEO of Harbour Biomed. Before founding HBM, he was the Head of China Research and Development and of Translational Medicine, Asia Pacific, for Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for pre-clinical and clinical assets. Dr. Wang completed his Clinical Rheumatology Fellowship and was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang earned his PhD in Molecular Pharmacology from China Pharmaceutical University and also completed a Molecular Immunology Research Fellowship at the Harvard School of Public Health.
Members
  • Xiaochun Cao

    Executive Vice President & Board Secretary, Tigermed Consulting Ltd.

  • George Chen

    Senior VP, Global Medicines Development, Head of China Development Unit, AstraZeneca China

  • Hannah Chen

    Former Director, CQA/PV China, Jansen Pharm R&D QA, Johnson & Johnson

  • Jin Cui

    Division of External Cooperation, China Center for Food and Drug International Exchange (CCFDIE)

  • Irene Deng

    Head of Regulatory Affairs, China, Sanofi

  • Tong Guo

    Vice President and Head of Sales, Greater China IQVIA

  • Xiang GUO

    Executive Director, Head of Biometrics China, BeiGene (Beijing) Co., Ltd.

  • Pei HU

    Director, Phase I Unit, Clinical Pharmacological Research Center, Peking Union Medical College

  • Benny LI

    Chief Medical Officer, TigerMed

  • Howe Li

    Chairman and CEO, Beijing DeltaMed Co. Ltd

  • Jian Li

    Vice President, Domestic Discovery Service Unit, WuXi AppTec

  • Melly Lin

    Senior Regulatory Manager, CMC Policy,, Roche(China) Holding Ltd

  • Daniel Liu

    Chief Scientific Officer, Beijing Clinical Service Center

  • George LIU

    Head of Early Development and Scientific Operation, Harbour Biomed

  • Yanfei Liu

    Director of GCP, Fudan University Shanghai Cancer Center

  • Zhengqing Li

    Global Vice President and General Manager, China R&D Center, MSD

  • Shun Lu

    Director, Center for Clinical Medicine of Lung Cancer, Shanghai Chest Hospital, Shanghai Jiaotong University

  • Reako Ren

    Head of SMO Services, WuXi Apptec.

  • Ying Shao

    Former Vice President and Director of R&D Center, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

  • Xue TANG

    Drug Safety Unit Regional Head (DRH),, APAC Pfizer

  • Amber Wang

    Vice President, Regulatory Affairs & QA, SmithNephew

  • Li L Wang

    Senior Vice President, Lilly China Drug Development and Medical Affairs Center, Eli Lily & Company

  • Lin Wang

    VP, Leader of Asia Development Center, Takeda

  • Xiuqin Wang

    Vice Director of Scientific Research Dept., Jiangsu Province Hospital

  • Zaiqi Wang

    Former Head, Early Medical, Roche (Chine) Holding Ltd.

  • Jielai Xia

    Director, Department of Medical Statistics, Air Force Military Medical University

  • Charles Yan

    Senior Director, Data Management and Biometric, Shanghai Hengrui Medicine Co, LTD

  • Wendy Yan

    Senior Vice President, Head of Regulatory Affairs, BeiGene (Beijing) Co., Ltd.

  • Bin Yuan

    Senior Vice President, Global Head of Corporate Development, CStone Pharmaceuticals

  • Mingqiang Zhang

    General Manager, Corporate VP of R&D, Amgen BioPharmaceutical R&D (Shanghai) Co., Ltd

  • Dayao ZHAO

    Former Vice President and Lead, China Drug Development, Pfizer

  • Sunny Zhu

    Chief Medical Officer, Infectious Diseases, Everest Medicines

  • Xiangyang Zhu

    CEO, Shanghai Huaota Biopharma Co., Ltd